EU to provide incentives for “orphan” drugs

The European Union has introduced new legislation designed to encourage pharmaceutical companies to develop treatments for “orphan” (rare)diseases that affect fewer than five people in every 10000 within the 15 member bloc.

Since the beginning of this month companies have been able to apply to the London based European Agency for the Evaluation of Medicinal Products …